ALNA · Allena Pharmaceuticals Inc

-

Please sign in to comment on ALNA

1 Comment

Admin

4 years, 1 month ago

Allena Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 16.0% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Allena Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 9.7% to $-10M since the same quarter in the previous year.

Finally, its free cash flow grew by 29.3% to $-9M since the same quarter in the previous year.

Based on the above factors, Allena Pharmaceuticals, Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US0181191075
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Market Cap	9M
Beta	1.15
Target Price	4
Dividend Yield	0.0%

ABOUT

Allena Pharmaceuticals Inc

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

ALNA · Allena Pharmaceuticals Inc

-

Allena Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Allena Pharmaceuticals Inc using a moving average strategy